Subconjunctival Bevacizumab and Recurrent Pterygium
- Sponsor
- Instituto de Olhos de Goiania
- Study ID
- NCT01744756
- Phase
- PHASE2/PHASE3
- Status
- Completed
Conditions
- Recurrent Pterygium
Eligibility Criteria
- Sex
- ALL
- Age
- 40 Years - 80 Years
- Healthy Volunteers
- Not accepted
Interventions
- Bevacizumab — DRUGOne subconjunctival aplication of Bevacizumabe 0,5ml
Study Details
A study to research whether subconjunctival bevacizumab injection may potentially suppress neovascularization in pterygium, retarding and decreasing the size of recurrent pterygium.
Key Dates
- First listed
- Dec 7, 2012
- Start date
- Feb 29, 2012
- Status verified
- Dec 2012
- Primary completion
- Jul 31, 2012
- Completion
- Sep 30, 2012
Study Design
- Enrollment
- 36 participants (actual)
- Allocation
- NA
- Intervention model
- SINGLE_GROUP
- Primary purpose
- TREATMENT
Arms
- Experimental: Subconjunctival BevacizumabOne aplication of subconjunctival Bevacizumab 0,5 ml
Primary Outcome Measure
Pterygium size after subconjunctival bevacizumab [ Time Frame: 8 weeks ]